Nexalin Technology

Nexalin Technology Equity

The The Equity of Nexalin Technology (NXL) as of Nov 19, 2026 is 3.75 M USD. In the previous year, The Equity was 3.68 M USD — a change of 1.96% (higher).

Equity

3.75 MUSD

YoY

1.96%

Last updated:

In 2025, Nexalin Technology's equity was 3.75 M USD, a 1.96% increase from the 3.68 M USD equity in the previous year.

The Nexalin Technology Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-1.18 M USD
Jan 1, 2020
-1.59 M USD
Jan 1, 2021
-1.68 M USD
Jan 1, 2022
5.48 M USD
Jan 1, 2023
3.21 M USD
Jan 1, 2024
3.68 M USD
Jan 1, 2025
3.75 M USD
The Nexalin Technology Equity history
YEAREquityYoY
3.75 MUSD+1.96%
3.68 MUSD+14.64%
3.21 MUSD-41.47%
5.48 MUSD-425.74%
-1.68 MUSD+5.76%
-1.59 MUSD+34.85%
-1.18 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Nexalin Technology's Equity

Nexalin Technology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Nexalin Technology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Nexalin Technology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Nexalin Technology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Nexalin Technology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Nexalin Technology stock

The Equity of Nexalin Technology is 3.75 M USD in 2025.

The Equity of Nexalin Technology changed from 3.68 M USD to 3.75 M USD, representing a 1.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Nexalin Technology

All Key Metrics — Nexalin Technology